NCT01989520View on ClinicalTrials.gov

Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Uncontrolled and Persistent Asthma
Interventions
DRUG

Phase IIb formulation

Single oral dose 45mg AZD5069

DRUG

Putative phase III formulation

Single oral dose 45mg AZD5069

DRUG

Slow dissolution variant 1

Single oral dose 45mg AZD5069

DRUG

Slow dissolution variant 2

Single oral dose 45mg AZD 5069

DRUG

Test treatment E

Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY